Market news
ProQR Therapeutics (PRQR) said Wednesday it has dosed the first participant in a phase 1 trial of AX
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage ...
Buy ProQR Therapeutics N.V.: Axiomer RNA editing shows strong phase 1 proof-of-concept for biliary atresia; key 2026–27 catalysts ahead. Click to read more.
Bank of America starts ProQR at buy with $8 target, citing validated Axiomer RNA-editing and AX-0810 upside in cholestasis. Read more here.
First clinical validation of Axiomer™ RNA editing established through NTCP modulation with positive AX-0810 clinical target engagement data; full Phase 1 dataset to be presented at a medical or scientific conference later this yearMultiple clinical milestones, including initial AX-0811 Phase 1 data expected by year-end 2026, followed in H1 2027 by: biliary atresia IIT initiation and initial data, initial AX-0422 (IDUA) patient data in MPS I Hurler syndrome, and advancement of AX-2911 (PNPLA3) to
Bart Filius, Director, on July 17, 2026, executed a purchase for 150,000 shares in Proqr Therapeutic
This is the newest page. Registered accounts read further back.